PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 14, 2026Open Forum Infectious Diseases0 citationsOpen Access

P-139. Prophylactic Antibiotics for Transcatheter Aortic Valve Implantation (TAVI) at a UK Cardiothoracic Centre

View Full Paper
ABAngel BoulosAMAlexander MartinMKMonika Kalra

Key Points

  • To evaluate antibiotic prophylaxis practices for TAVI and align with ESC guidelines.
  • Retrospective review of antibiotic prescriptions at James Cook University Hospital from April to November 2023
  • Identified cases of TAVI-related endocarditis from January 2022 to January 2024 via IE MDT records and ICD-coded data
  • Review findings with microbiology, infectious diseases, and cardiology services.
  • Among 115 prescriptions for 112 patients, 88% received cefuroxime 1.5g IV, and 12% received Teicoplanin 400mg IV
  • Only Teicoplanin covered Enterococcus spp. as required
  • No patients received prophylaxis aligned with current ESC guidelines
  • Three cases of TAVI-related endocarditis identified, with Enterococcus faecalis among causative agents.

Abstract

Abstract Background TAVI is an increasingly used alternative to surgical aortic valve replacement. Infective endocarditis post TAVI, while uncommon, is a serious complication, with Enterococcus spp. frquently implicated. In 2023, the European Society of Cardiology(ESC) issued updated Endocarditis guidelines recommending prophylaxis with activity against Enterococcus spp. prior to TAVI(Delgado teal., Eur Heart J, 2023). Local guidance at our institution had not previously addressed this.Figure 1:Antibioitic prescriptions for TAVI Methods A retrospective review of electronic antibiotic prescriptions for TAVI was performed at James Cook University Hospital between April and November 2023. Cases of TAVI-related Endocarditis from January 2022 to January 2024 were identified via IE MDT records and ICD-coded hospital data. Findings were reviewed with microbiology, infectious diseases, and cardiology services. Results Among 115 prescriptions for 112 patients, 101(88%) received cefuroxime 1.5g IV monotherapy, and 14(12%) received Teicoplanin 400mg IV monotherapy. Only Teicoplanin provided Enterococcus coverage. No patient received prophylaxis aliged with ESC or local guidance. Three cases of TAVI-related IE were identified: Enterococcus faecalis, Streptococcus oxalis, and Streptococcus gordonii. These findings informed he development of a revised prophylactic regimen incorporating specific coverage for Enterococcus spp., agreed upon through multidisciplinary collaboration. Conclusion At our centre, the most patients undergoing TAVI did not receive prophylaxis with appropriate Enterococcus spp coverage, falling short of current ESC guideline recommendations. These findings prompted the development and implementation of a new institutional guideline, which will be monitered through prospective study. Addtionally, there is a pressing need for a dedicated TAVI endocarditis database to inform national and international prophylaxis strategies based on robust epidemiological data. Disclosures All Authors: No reported disclosures

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Boulos et al. (2026) studied this question.

synapsesocial.com/papers/6966f33b13bf7a6f02c012e8https://doi.org/10.1093/ofid/ofaf695.366
Ask AI
Helpful
Bookmark
Share
View Full Paper